KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Short-term Investments (2018 - 2025)

Takeda Pharmaceutical (TAK) has 4 years of Short-term Investments data on record, last reported at $134.2 million in Q1 2025.

  • For Q1 2025, Short-term Investments rose 31.82% year-over-year to $134.2 million; the TTM value through Mar 2025 reached $134.2 million, up 31.82%, while the annual FY2025 figure was $134.4 million, 28.47% up from the prior year.
  • Short-term Investments reached $134.2 million in Q1 2025 per TAK's latest filing, up from $101.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $345.8 million in Q1 2021 and bottomed at $101.8 million in Q1 2024.
  • Average Short-term Investments over 3 years is $193.9 million, with a median of $134.2 million recorded in 2025.
  • Peak YoY movement for Short-term Investments: soared 137.94% in 2021, then surged 31.82% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $345.8 million in 2021, then crashed by 70.55% to $101.8 million in 2024, then soared by 31.82% to $134.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $134.2 million in Q1 2025, $101.8 million in Q1 2024, and $345.8 million in Q1 2021.